A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

NCT06214143 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL: T3011 high dose
BIOLOGICAL: T3011 middle dose
BIOLOGICAL: T3011 low dose

Sponsor

Shanghai Pharmaceuticals Holding Co., Ltd